PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34410944-0	2021	Induction of Apoptosis and Inhibition of EGFR/NF-kappaB Signaling Are Associated With Regorafenib-sensitized Non-small Cell Lung Cancer to Cisplatin.	Cisplatin	139-148	epidermal growth factor receptor	Homo sapiens	41-45	
34410944-5	2021	RESULTS: Cisplatin-induced epidermal growth factor receptor (EGFR)/nuclear factor kappaB (NF-kappaB) signaling was effectively inhibited by regorafenib treatment.	Cisplatin	9-18	epidermal growth factor receptor	Homo sapiens	27-59	
34410944-5	2021	RESULTS: Cisplatin-induced epidermal growth factor receptor (EGFR)/nuclear factor kappaB (NF-kappaB) signaling was effectively inhibited by regorafenib treatment.	Cisplatin	9-18	epidermal growth factor receptor	Homo sapiens	61-65	
34410944-6	2021	Regorafenib, erlotinib (EGFR inhibitor) and QNZ (NF-kappaB inhibitor) may all enhance the cytotoxicity effect of cisplatin.	Cisplatin	113-122	epidermal growth factor receptor	Homo sapiens	24-28	
34410944-9	2021	CONCLUSION: Apoptosis induction and EGFR/NF-kappaB inactivation correlate with regorafenib-enhanced anti-NSCLC efficacy of cisplatin.	Cisplatin	123-132	epidermal growth factor receptor	Homo sapiens	36-40